High-Resolution Contrast-Enhanced, Susceptibility-Weighted MR Imaging at 3T in Patients with Brain Tumors: Correlation with Positron-Emission Tomography and Histopathologic Findings

BACKGROUND AND PURPOSE: The purpose of this work was to demonstrate susceptibility effects (SusE) in various types of brain tumors with 3T high-resolution (HR)-contrast-enhanced (CE)-susceptibility-weighted (SW)-MR imaging and to correlate SusE with positron-emission tomography (PET) and histopathology. MATERIALS AND METHODS: Eighteen patients with brain tumors, scheduled for biopsy or tumor extirpation, underwent high-field (3T) MR imaging. In all of the patients, an axial T1-spin-echo (SE) sequence and an HR-SW imaging sequence before and after IV application of a standard dose of contrast agent (MultiHance) was obtained. Seven patients preoperatively underwent PET. The frequency and formation of intralesional SusE in all of the images were evaluated and correlated with tumor grade as determined by PET and histopathology. Direct correlation of SusE and histopathologic specimens was performed in 6 patients. Contrast enhancement of the lesions was assessed in both sequences. RESULTS: High-grade lesions demonstrated either high or medium frequency of SusE in 90% of the patients. Low-grade lesions demonstrated low frequency of SusE or no SusE. Correlation between intralesional frequency of SusE and histopathologic, as well as PET, tumor grading was statistically significant. Contrast enhancement was equally visible in both SW and SE sequences. Side-to-side comparison of tumor areas with high frequency of SusE and histopathology revealed that intralesional SusE reflected conglomerates of increased tumor microvascularity. CONCLUSIONS: 3T HR-CE-SW-MR imaging shows both intratumoral SusE not visible with standard MR imaging and contrast enhancement visible with standard MR imaging. Because frequency of intratumoral SusE correlates with tumor grade as determined by PET and histopathology, this novel technique is a promising tool for noninvasive differentiation of low-grade from high-grade brain tumors and for determination of an optimal area of biopsy for accurate tumor grading.

[1]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[2]  Petra Schmalbrock,et al.  Susceptibility-based imaging of glioblastoma microvascularity at 8 T: correlation of MR imaging and postmortem pathology. , 2004, AJNR. American journal of neuroradiology.

[3]  J R Reichenbach,et al.  High Resolution Susceptibility Weighted MR-Imaging of Brain Tumors during the Application of a Gaseous Agent , 2005, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[4]  H. An,et al.  Improving high‐resolution MR bold venographic imaging using a T1 reducing contrast agent , 1999, Journal of magnetic resonance imaging : JMRI.

[5]  I. Nöbauer-Huhmann,et al.  The optimal use of contrast agents at high field MRI , 2006, European Radiology.

[6]  J. Reichenbach,et al.  Contrast-Enhanced, High-Resolution, Susceptibility-Weighted Magnetic Resonance Imaging of the Brain: Dose-Dependent Optimization At 3 Tesla and 1.5 Tesla In Healthy Volunteers , 2006, Investigative radiology.

[7]  O. Seror,et al.  L'imagerie de susceptibilité magnétique: Théorie et applications , 2004 .

[8]  J. R. Reichenbach,et al.  High-resolution blood oxygen-level dependent MR venography (HRBV): a new technique , 2001, Neuroradiology.

[9]  J. Reichenbach,et al.  Magnetic susceptibility-weighted MR phase imaging of the human brain. , 2005, AJNR. American journal of neuroradiology.

[10]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[11]  J. Schramm,et al.  Low-Grade Gliomas - Current Concepts , 2006, Zentralblatt fur Neurochirurgie.

[12]  Markus Barth,et al.  High-Resolution Three-Dimensional Contrast-Enhanced Blood Oxygenation Level-Dependent Magnetic Resonance Venography of Brain Tumors at 3 Tesla: First Clinical Experience and Comparison with 1.5 Tesla , 2003, Investigative radiology.

[13]  O Salonen,et al.  MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. , 1999, Investigative radiology.

[14]  J R Reichenbach,et al.  Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. , 1997, Radiology.

[15]  E. Haacke,et al.  [Susceptibility weighted imaging. Theory and applications]. , 2004, Journal de radiologie.

[16]  J R Griffiths,et al.  Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. , 1998, Seminars in radiation oncology.

[17]  Edward Pan,et al.  Glioblastoma Multiforme and Anaplastic Astrocytoma , 2003 .

[18]  E. Haacke,et al.  High‐resolution BOLD venographic imaging: a window into brain function , 2001, NMR in biomedicine.

[19]  Susan M. Chang,et al.  Diagnosis and treatment of recurrent high-grade astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Petra Schmalbrock,et al.  Visualization of microvascularity in glioblastoma multiforme with 8-T high-spatial-resolution MR imaging. , 2002, AJNR. American journal of neuroradiology.

[21]  L R Schad,et al.  Improved target volume characterization in stereotactic treatment planning of brain lesions by using high‐resolution BOLD MR‐venography , 2001, NMR in biomedicine.

[22]  Christopher Nimsky,et al.  Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. , 2006, Radiology.

[23]  Lothar R. Schad,et al.  High-resolution venography of the brain using magnetic resonance imaging , 1998, Magnetic Resonance Materials in Physics, Biology and Medicine.

[24]  Yu-Chung N. Cheng,et al.  Susceptibility weighted imaging (SWI) , 2004, Zeitschrift fur medizinische Physik.

[25]  Jaladhar Neelavalli,et al.  Susceptibility‐weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses , 2006, Journal of magnetic resonance imaging : JMRI.

[26]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[27]  M. Kitajima,et al.  Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI , 2002, Neuroradiology.

[28]  J R Reichenbach,et al.  High-Resolution MR Venography at 3.0 Tesla , 2000, Journal of computer assisted tomography.

[29]  Siegfried Trattnig,et al.  Effect of Contrast Dose and Field Strength in the Magnetic Resonance Detection of Brain Metastases , 2003, Investigative radiology.

[30]  M. Lesniak,et al.  Surgical management of high-grade gliomas , 2005, Expert review of neurotherapeutics.

[31]  R I Grossman,et al.  Gliomas: correlation of magnetic susceptibility artifact with histologic grade. , 1997, Radiology.

[32]  L. Recht,et al.  Low-grade gliomas. , 1995, Neurologic clinics.

[33]  Jaladhar Neelavalli,et al.  Clinical applications of neuroimaging with susceptibility‐weighted imaging , 2005, Journal of magnetic resonance imaging : JMRI.